2-10 Home Buyers Warranty Kicks Off National Homeownership Month
Leading new home warranty company continues to enhance the home builder and buyer experience
DENVER, May 29, 2025--(BUSINESS WIRE)--2-10 Home Buyers Warranty — a Frontdoor, Inc. (NASDAQ: FTDR) company and a leading administrator of builder warranties — is celebrating June's National Homeownership Month by continuing to support home builders and home buyers with high-quality warranty services that enhance their experience.
"National Homeownership Month is a perfect time to highlight how adding 2-10 to the Frontdoor portfolio is a huge win for home builders and home buyers who work with us," said Frontdoor's Chief Revenue Officer Kathy Collins. "Our members can now take advantage of a unique combination — 2-10's 40-plus years of expertise in the new home structural warranty space and Frontdoor's industry-leading suite of home warranties and on-demand services."
National Homeownership Month has been an industry-wide celebration since June 2002. In this spirit, 2-10 continues to enhance its New Home Warranty program, post-closing customer-care support and home service plan offerings.
"We are laser-focused on supporting our customers," said Libby Snead, VP and General Manager of the 2-10 New Home Team at Frontdoor. "In speaking with builders specifically, the challenge they're facing is how to provide outstanding customer care after the home sale. 2-10 is ready to support them with unmatched expertise."
"Moving forward, we anticipate adding more enhancements to our New Home products and services, specifically in terms of warranty administration support," Snead said.
For more information about 2-10, please visit www.2-10.com.
About 2-10
Founded and based near Denver, the 2-10 family of companies has products covering over 6 million homes with their complete line of builder warranties and home service plans. Since 1980, 2-10 has been a market leader in helping builders, real estate agents and homeowners protect their businesses and budgets against the unexpected. 2-10 continues to work with thousands of the nation's finest real estate professionals, home builders and service contractors. For more information about 2-10, please visit 2-10.com.
About Frontdoor, Inc.
Frontdoor is the industry leader in home warranties and new home structural warranties, and a leading provider of on-demand home repair and maintenance services. As the parent company of two leading brands — American Home Shield and 2-10 Home Buyers Warranty — totaling more than two million members – we bring over 50 years of experience in the home warranty category, a cultivated national network of independent service contractors, and a reputation for delivering quality service and product innovation. American Home Shield, the leader in home warranties, gives homeowners peace of mind, budget protection and convenience, covering up to 23 home systems and appliances from costly and unexpected breakdowns. 2-10 Home Buyers Warranty is the leader in new home structural warranties, providing home builders with coverage for structural failures. These two brands, together with Frontdoor's cutting-edge on-demand services, provide an unbeatable combination that meets the full suite of homeowner repair and maintenance needs. For more information about Frontdoor, Inc., please visit frontdoorhome.com.
Forward Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements, because actual results may vary materially from those expressed or implied. The reports filed by Frontdoor pursuant to United States securities laws contain discussions of these risks and uncertainties. Frontdoor assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review Frontdoor's filings with the United States Securities and Exchange Commission (which are available on the SEC's EDGAR database at www.sec.gov and via Frontdoor's website at investors.frontdoorhome.com).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529100918/en/
Contacts
Alison Bishop901.701.5198mediacenter@ahs.com Tom Collins901.701.5198
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
Treasury Options Skew June 2025
Implied volatility in options on Treasury futures has drifted lower since April, but the skew—particularly in the belly of the curve—remains a focal point. As traders prepare for a data-heavy June, including Non-Farm Payrolls, CPI and the FOMC, the behavior of skew and CVOL in the Ultra 10-Year (UXY) futures complex offers a revealing lens into how rate risk is being priced. Downside skew in Treasury options—especially on 5-Year (FV), 10-Year (TY) and Ultra 10-Year (UXY) futures—remains elevated. TYVY, the CVOL Index for 10-Year Treasury options, has declined from April highs but is still holding in the 115–120 range. Key macro events ahead: Non-Farm Payrolls – Friday, June 6 . Consumer Price Index (CPI) – Wednesday, June 12. FOMC Statement – Wednesday, June 18, 2:00 p.m. ET; press conference at 2:30 p.m. ET. PCE Price Index – Friday, June 27. Despite the decline in overall volatility, downside skew remains persistent, particularly in UXY and FV options. Traders continue to assign higher premiums to puts relative to calls, reflecting structural demand for downside hedges or latent concerns about fiscal risk, policy missteps or supply shocks. As we approach the June 6 jobs report, and especially the June 18 FOMC decision, this skew could be tested. Traders can use CVOL to see TVL or volatility indices for 2-, 5-, 10-Year and Bond futures. For volatility on options like the growing option volume on Ultra 10-Year futures consider QuikVol's QuikSkew analytics. The 2s10s curve steepened in May, reviving interest in conditional curve trades using options to express directional views on curve shape. Options are increasingly being used to express conditional curve trades. Call spreads in FV versus put spreads in UXY. Butterfly structures around inflection points in UXY to capture steepening potential without excessive Vega exposure. TYVY skew, built on deep liquidity from options on 10-Year Note futures, supports this theme. Depending on one's risk management strategy, options on 10-Year Note futures or options on Ultra 10-Year futures retain more downside premium relative to other tenors. We have expanded our suite of Treasury options with the addition of Tuesday and Thursday expiries, significantly enhancing the flexibility of short-dated hedging strategies. This update allows market participants to position tactically around high-impact economic releases such as Non-Farm Payrolls, CPI and FOMC decisions, by accessing expiries available every trading day of the week, two weeks forward. This enhancement is especially valuable in environments with compressed risk windows, intraday volatility bursts, or when event timing doesn't align neatly with the traditional Monday/Wednesday/Friday expiration schedule. The change was detailed in CME Group SER-9566R. With the macro spotlight on June 6 and June 18, options on Treasury futures offer deep insight into how rate risk is being repriced. Skews in UXY options, the behavior of TVL and renewed activity in curve-based option structures all point to a market that sees risk beneath the surface. Whether you're watching TVL or the new Tuesday and Thursday expiries, June will be a month to track the message inside the vol surface. All examples in this report are hypothetical interpretations of situations and are used for explanation purposes only. The views in this report reflect solely those of the author and not necessarily those of CME Group or its affiliated institutions. This report and the information herein should not be considered investment advice or the results of actual market experience. Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service. All examples in this report are hypothetical interpretations of situations and are used for explanation purposes only. The views in this report reflect solely those of the author and not necessarily those of CME Group or its affiliated institutions. This report and the information herein should not be considered investment advice or the results of actual market experience. CME Group Inc. does not have control over the content, accuracy, quality, or legality, of any third-party product, service, or content advertised on this webpage. The presence of such advertisements on this webpage does not signify any association, partnership, or endorsement of the third-party or its content by CME Group Inc. Full disclaimer Copyright © 2025 CME Group Inc.
